Select An Issue
Selected Issue:
Issue 5
8th
March 2010
C&I Magazine
C&I MagazineThe leading source of news and opinion in the arena of chemical technology
Cover Story
R&D budgets are holding up in some companies but how can the benefits
be measured? Neil Eisberg reports
News
Emma Dorey,
08/03/2010
Drug giant AstraZeneca has
signed a $1.3bn deal to develop
and commercialise a drug to treat
rheumatoid arthritis.
Cath O’Driscoll,
08/03/2010
US plans to curb emissions of
greenhouse gases have come under
fire in recent weeks after a spate of
announcements from industry groups,
oil majors and three US states.
Features
Chris Frampton,
08/03/2010
Formulating drugs as cocrystals could overcome the solubility
problems hampering the development of some active pharma
ingredients, reports Chris Frampton
Lou Reade,
08/03/2010
Textiles that incorporate biosensors, or act as heat sinks, or mimic human bone are
racing towards commercialisation. Lou Reade reports
Editor's Blog
An end to jet lag?
Agree or disagree? Post your views below
Can it be true, an end to jet lag, the bane of all international jet-setters? But could the answer also be a solution to a host of other problems including psychiatric disorders and the impact of shift work?
As Andrew Loudon from the University of Manchester says: ‘It can be really devastating to our brains and bodies when something happens to disrupt the natural rhythm of our body clocks. This can be as a result of disease or as a consequence of jet lag or frequent changing between day and night shifts at work.’